<DOC>
	<DOC>NCT02288273</DOC>
	<brief_summary>A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.</brief_summary>
	<brief_title>Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.</brief_title>
	<detailed_description>A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in 110 Metformin-treated Patients with Type 2 Diabetes</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus (T2DM) treated with stable dose of metformin &gt; or = to 1500mg/day as monotherapy for at least 8 weeks Hemoglobin A1c (HbA1c) 7% to 10% at screening Body mass index (BMI) &lt; or = to 45 kg/m2 History of taking antihyperglycemic therapy other than metformin or metformin extended release (XR) during the 8 weeks prior to screening History of taking a dipeptidyl peptidase4 (DPP4) inhibitor or pramlintide during 12 weeks prior to screening History of potent, inhaled or intrapulmonary steroids 3 months prior to screening or during the study History of prescription or over the counter weight loss medication during 3 months prior to screening Previous exposure to exenatide or any glucagonlike peptide1 (GLP1) receptor agonist during 6 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>